Companies

Search, filter and compare every US company we cover.

Search companies

Sector

Industry

Size

Today

Profitable Growing

Add filter

Clear all

916 companies match

Sort by

Market cap

Lowest first

Company	Industry	Market cap	Price	Day change	Revenue	Revenue growth	Operating margin	P/E	5-yr growth	Gross margin	Net margin	Free cash flow	FCF margin	Return on capital	Return on equity	Net debt	Net debt / EBITDA	Dividends + buybacks	Share count change	F-score	Insider buys (90d)	Insider sales (90d)
Omeros CorpOMER	Pharmaceutical Preparations	$1.6B	$17.49	7.4%	—	—	—	10.1x	—	—	—	−$116M	—	—	—	−$82.7M	—	$0.0M	—	—	$0.0M	$2.2M
Taysha Gene Therapies, Inc.TSHA	Biological Products, (No Diagnostic Substances)	$1.6B	$4.25	6.0%	$9.8M	17.3%	−1,130.6%	—	—	—	−1,115.3%	−$93.8M	−960.1%	—	−68.5%	−$269M	—	—	27.8%	4	$0.0M	$0.0M
Phibro Animal Health CorpPAHC	Pharmaceutical Preparations	$1.6B	$38.38	1.7%	$1.5B	17.1%	12.8%	15.8x	12.7%	33.8%	6.6%	$9.9M	0.6%	—	29.7%	—	—	$19.5M	0.7%	6	$0.0M	$0.0M
COMPASS Pathways plcCMPS	Pharmaceutical Preparations	$1.6B	$11.81	6.9%	—	—	—	—	—	—	—	—	—	—	−565.3%	−$100M	—	—	38.6%	1	$0.0M	$0.0M
Immunocore Holdings plcIMCR	Biological Products, (No Diagnostic Substances)	$1.6B	$31.96	2.2%	$400M	29.0%	−11.3%	—	—	98.7%	−8.9%	−$15.1M	−3.8%	—	−9.6%	—	—	—	0.7%	3	$0.0M	$0.0M
Intellia Therapeutics, Inc.NTLA	In Vitro & In Vivo Diagnostic Substances	$1.6B	$12.28	9.1%	$67.7M	16.9%	−651.7%	—	3.1%	—	−609.9%	−$396M	−585.0%	—	−53.5%	—	—	—	9.6%	2	$0.0M	$0.3M
Novavax IncNVAX	Biological Products, (No Diagnostic Substances)	$1.6B	$10.02	6.6%	$1.1B	64.7%	40.3%	—	18.8%	93.5%	39.2%	—	—	—	—	−$486M	−1.0x	—	13.7%	5	$0.0M	$0.0M
Absci CorpABSI	Services-Commercial Physical & Biological Research	$1.7B	$10.57	11.9%	$2.8M	−38.2%	−4,297.0%	—	−10.1%	—	−4,113.7%	−$94.0M	−3,358.3%	—	−62.5%	—	—	—	24.1%	2	$0.0M	$0.0M
Eton Pharmaceuticals, Inc.ETON	Pharmaceutical Preparations	$1.7B	$51.16	2.0%	$80.0M	104.9%	−1.1%	—	359.6%	53.5%	−5.8%	$10.2M	12.7%	−1.7%	−18.2%	$13.4M	4.2x	—	—	4	$0.0M	$10.9M
Personalis, Inc.PSNL	Services-Medical Laboratories	$1.7B	$15.98	0.6%	$69.6M	−17.7%	−126.4%	—	−2.4%	22.7%	−116.7%	−$79.5M	−114.1%	—	−35.0%	—	—	—	50.6%	3	$0.0M	$0.3M
CertaraCERT	Health Care Technology	$1.7B	$10.95	3.2%	$419M	8.8%	5.0%	—	11.5%	—	−0.4%	$94.6M	22.6%	0.9%	−0.2%	$104M	1.1x	$42.6M	0.0%	5	$0.0M	$0.0M
Healthcare Services Group IncHCSG	Services-Nursing & Personal Care Facilities	$1.7B	$24.37	3.0%	$1.8B	7.1%	—	16.5x	0.9%	13.0%	3.2%	$139M	7.6%	—	11.7%	—	—	$61.6M	−1.3%	7	$0.0M	$0.4M
Ardent Health, Inc.ARDT	Services-General Medical & Surgical Hospitals, Nec	$1.7B	$11.83	2.9%	$6.3B	6.0%	—	21.5x	—	—	2.1%	—	—	—	11.2%	$431M	—	—	6.6%	5	$0.0M	$0.0M
NovoCure LtdNVCR	Surgical & Medical Instruments & Apparatus	$1.7B	$14.62	1.5%	$655M	8.3%	−23.5%	—	5.8%	74.5%	−20.8%	−$75.7M	−11.5%	−27.5%	−38.9%	$101M	—	—	3.4%	3	$0.0M	$0.0M
Alphatec Holdings, Inc.ATEC	Surgical & Medical Instruments & Apparatus	$1.7B	$10.87	0.3%	$764M	25.0%	−10.7%	—	39.5%	69.6%	−18.8%	$2.8M	0.4%	−13.5%	—	$470M	—	—	5.0%	5	$1.0M	$0.1M
Mesoblast LtdMESO	Biological Products, (No Diagnostic Substances)	$1.7B	$13.18	6.4%	$120M	599.2%	—	—	74.5%	86.1%	−47.8%	−$44.7M	−37.1%	—	−9.9%	$16.3M	—	—	7.2%	6	$0.0M	$0.0M
Ultragenyx Pharmaceutical Inc.RARE	Pharmaceutical Preparations	$1.7B	$16.75	4.2%	$673M	20.2%	−79.5%	—	19.9%	—	−85.4%	−$472M	−70.1%	—	−657.1%	—	—	—	9.0%	4	$0.0M	$0.3M
Zenas BioPharma, Inc.ZBIO	Pharmaceutical Preparations	$1.7B	$27.30	0.2%	$10.0M	100.0%	−3,830.6%	—	—	—	−3,777.4%	−$172M	−1,723.5%	—	−136.2%	−$265M	—	—	238.9%	2	$0.0M	$0.0M
Stoke Therapeutics, Inc.STOK	Pharmaceutical Preparations	$1.7B	$26.13	2.6%	$184M	404.5%	−11.2%	—	—	—	−3.7%	$44.9M	24.4%	—	−2.4%	—	—	—	9.6%	4	$0.0M	$1.1M
Alignment HealthcareALHC	Health Care Services	$1.7B	$8.05	2.0%	$3.9B	46.1%	0.4%	42.4x	32.7%	—	−0.0%	$113M	2.9%	—	−0.5%	−$281M	−6.2x	$0.0M	3.8%	5	$0.0M	$13.7M
Kestra Medical Technologies, Ltd.KMTS	Surgical & Medical Instruments & Apparatus	$1.8B	$29.99	1.9%	$95.1M	59.0%	−141.6%	—	—	51.4%	−138.4%	−$117M	−122.6%	−100.5%	−56.6%	−$154M	—	—	120.4%	5	$0.0M	$9.2M
AzentaAZTA	Life Sciences Tools & Services	$1.8B	$39.08	5.1%	$594M	3.6%	−4.5%	—	8.9%	45.5%	−9.4%	$38.3M	6.5%	—	−3.2%	—	—	$0.0M	−13.7%	—	$0.0M	$0.0M
Mineralys Therapeutics, Inc.MLYS	Pharmaceutical Preparations	$1.8B	$21.13	2.8%	—	—	—	—	—	—	—	−$142M	—	—	−36.9%	—	—	—	39.4%	—	$0.0M	$5.5M
Xeris Biopharma Holdings, Inc.XERS	Pharmaceutical Preparations	$1.8B	$10.45	2.4%	$292M	43.7%	8.5%	—	70.2%	—	0.2%	—	—	20.2%	—	$109M	4.2x	—	17.7%	7	$0.0M	$1.2M
Astrana HealthASTH	Health Care Facilities	$1.8B	$36.94	0.8%	$3.2B	56.4%	2.5%	44.5x	35.9%	—	0.7%	$104M	3.3%	4.2%	3.0%	$609M	4.9x	$33.5M	2.9%	4	$0.0M	$0.0M
Amn Healthcare ServicesAMN	Health Care Services	$1.9B	$46.81	4.5%	$2.7B	−8.5%	−2.0%	17.4x	2.7%	28.4%	−3.5%	$234M	8.6%	−2.8%	−14.2%	$733M	7.3x	$0.0M	0.9%	5	$0.0M	$0.0M
GeneDx Holdings Corp.WGS	Services-Health Services	$1.9B	$62.74	2.4%	$428M	40.0%	−3.1%	—	19.0%	69.7%	−4.9%	$14.3M	3.3%	−5.4%	−7.6%	−$98.9M	—	—	6.5%	6	$0.0M	$1.8M
Maze Therapeutics, Inc.MAZE	Biological Products, (No Diagnostic Substances)	$1.9B	$31.69	2.0%	—	—	—	—	—	—	—	−$113M	—	—	−599.0%	—	—	—	1,474.0%	—	$0.0M	$5.9M
Dentsply SironaXRAY	Health Care Supplies	$1.9B	$9.35	1.4%	$3.7B	−3.0%	−11.5%	—	2.0%	50.0%	−16.3%	$104M	2.8%	−9.9%	−36.5%	$2.0B	—	$128M	−1.9%	6	$0.0M	$0.0M
Palvella Therapeutics, Inc.PVLA	Pharmaceutical Preparations	$1.9B	$132.91	5.3%	$2.6M	303.4%	−1,490.4%	—	−38.5%	—	−1,610.6%	—	—	—	−92.1%	—	—	—	405.5%	2	$0.0M	$9.6M
Butterfly Network, Inc.BFLY	X-Ray Apparatus & Tubes & Related Irradiation Apparatus	$1.9B	$7.38	10.8%	$97.6M	19.0%	−88.5%	—	16.1%	46.9%	−79.0%	−$16.0M	−16.4%	—	−42.2%	—	—	—	16.7%	3	$1.0M	$37.6M
Vir Biotechnology, Inc.VIR	Biological Products, (No Diagnostic Substances)	$2.0B	$11.57	4.8%	$68.6M	−7.6%	−699.2%	—	−2.1%	100.0%	−638.9%	−$397M	−578.5%	—	−45.7%	—	—	—	1.7%	3	$0.0M	$0.0M
Septerna, Inc.SEPN	Pharmaceutical Preparations	$2.0B	$44.14	6.7%	$46.0M	4,174.5%	−148.6%	—	—	—	−106.4%	$110M	238.7%	—	−12.2%	—	—	—	347.5%	4	$0.0M	$40.6M
Sarepta Therapeutics, Inc.SRPT	Pharmaceutical Preparations	$2.0B	$18.89	5.1%	$2.2B	15.6%	−31.8%	—	32.4%	98.8%	−32.5%	−$307M	−14.0%	−53.7%	−53.5%	−$111M	—	$25.0M	−7.2%	4	$0.0M	$0.0M
Axogen, Inc.AXGN	Electromedical & Electrotherapeutic Apparatus	$2.0B	$37.46	1.5%	$225M	20.2%	−3.5%	—	14.9%	74.3%	−7.0%	−$2.9M	−1.3%	−4.6%	−13.5%	$6.9M	—	—	4.1%	5	$0.0M	$4.7M
Establishment Labs Holdings Inc.ESTA	Orthopedic, Prosthetic & Surgical Appliances & Supplies	$2.0B	$66.95	1.8%	$211M	27.1%	−18.5%	—	20.0%	69.3%	−24.2%	−$56.9M	−27.0%	−15.8%	−133.3%	$172M	—	—	5.2%	4	$0.0M	$0.0M
Schrodinger, Inc.SDGR	Pharmaceutical Preparations	$2.0B	$26.72	9.1%	$256M	23.3%	−65.2%	—	18.8%	55.7%	−40.4%	$12.5M	4.9%	—	−26.3%	—	—	—	1.1%	4	$0.0M	$0.9M
LeMaitre VascularLMAT	Health Care Equipment	$2.1B	$83.79	0.6%	$250M	13.5%	27.2%	29.4x	14.0%	71.5%	23.1%	$74.5M	29.8%	25.5%	15.8%	−$191M	−2.4x	$19.9M	0.7%	5	$0.0M	$0.0M
Trulieve Cannabis Corp.TRLV	Medicinal Chemicals & Botanical Products	$2.1B	$10.67	1.4%	$1.2B	−0.4%	12.1%	—	17.8%	60.2%	−10.3%	$229M	19.4%	9.1%	−10.2%	−$44.0M	−0.2x	—	0.7%	6	$0.0M	$0.0M
Inspire Medical SystemsINSP	Health Care Equipment	$2.1B	$71.30	0.4%	$912M	13.6%	5.6%	15.7x	51.2%	85.4%	16.0%	$78.5M	8.6%	14.2%	19.8%	−$308M	−4.8x	$175M	−2.6%	5	$0.0M	$0.1M
Trevi Therapeutics, Inc.TRVI	Pharmaceutical Preparations	$2.1B	$13.35	6.7%	—	—	—	—	—	—	—	−$42.1M	—	—	−30.2%	—	—	—	32.1%	—	$0.0M	$0.6M
Zymeworks Inc.ZYME	Pharmaceutical Preparations	$2.1B	$28.85	1.7%	$106M	38.9%	−87.3%	—	22.2%	—	−76.6%	−$34.5M	−32.6%	—	−26.7%	—	—	$41.7M	−0.6%	5	$0.0M	$0.4M
Immunome Inc.IMNM	Pharmaceutical Preparations	$2.1B	$18.77	4.9%	$6.9M	−23.2%	−3,228.8%	—	—	—	−3,060.0%	−$201M	−2,890.1%	—	−52.1%	—	—	—	49.0%	3	$0.0M	$5.7M
Biocryst Pharmaceuticals IncBCRX	Biological Products, (No Diagnostic Substances)	$2.1B	$8.10	2.8%	$875M	94.1%	39.0%	—	117.9%	97.8%	30.2%	$345M	39.4%	—	—	−$272M	−0.8x	—	5.8%	7	$0.0M	$0.0M
Vera Therapeutics, Inc.VERA	Pharmaceutical Preparations	$2.2B	$29.99	6.0%	—	—	—	—	—	—	—	−$242M	—	—	−50.7%	−$640M	—	$0.0M	16.1%	1	$0.0M	$1.3M
Recursion Pharmaceuticals, Inc.RXRX	Biological Products, (No Diagnostic Substances)	$2.2B	$4.05	6.6%	$74.7M	26.9%	−867.9%	—	79.9%	5.0%	−863.4%	−$378M	−506.5%	−126.0%	−59.5%	−$706M	—	—	63.2%	4	$0.0M	$0.6M
Harmony BiosciencesHRMY	Biotechnology	$2.2B	$37.95	3.0%	$869M	21.5%	24.0%	12.3x	40.3%	77.2%	18.3%	$348M	40.1%	48.9%	20.8%	−$612M	—	$0.0M	1.2%	5	$0.0M	$3.1M
PERRIGO Co plcPRGO	Pharmaceutical Preparations	$2.2B	$16.02	1.3%	$4.3B	−2.8%	−26.4%	—	0.8%	35.1%	−33.5%	$145M	3.4%	−14.6%	−39.3%	$3.2B	—	$159M	0.8%	4	$0.0M	$0.0M
Addus HomeCareADUS	Health Care Services	$2.2B	$121.24	0.1%	$1.4B	23.2%	9.7%	21.2x	13.2%	32.5%	6.7%	$104M	7.3%	9.4%	9.3%	$39.4M	0.3x	$0.0M	5.8%	5	$0.0M	$0.0M
Prestige Consumer Healthcare Inc.PBH	Pharmaceutical Preparations	$2.3B	$47.39	1.6%	$1.1B	−4.3%	28.4%	13.3x	2.9%	54.7%	17.5%	$246M	22.6%	8.1%	10.2%	$951M	2.8x	$156M	−2.7%	5	$0.0M	$0.0M

What do these columns mean?

Market cap: Last close times the latest diluted share count, so it is approximate.
Price: Closing share price on the last trading day.
Day change: Change in the closing price against the previous trading day's close.
Revenue: Total sales reported in the income statement.
Revenue growth: Change in revenue against the year (or quarter) a year earlier.
Operating margin: Operating income as a share of revenue.
P/E: Last close divided by diluted earnings per share over the last four quarters.
5-yr growth: Revenue growth a year, compounded over the last five years.
Gross margin: Gross profit as a share of revenue.
Net margin: Net income as a share of revenue.
Free cash flow: Cash from operations minus capital spending.
FCF margin: Free cash flow as a share of revenue.
Return on capital: After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Return on equity: Net income as a share of average shareholders' equity.
Net debt: Debt and finance leases minus cash and short-term investments. Negative means net cash.
Net debt / EBITDA: Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
Dividends + buybacks: Cash returned to shareholders through dividends and share repurchases.
Share count change: Change in the diluted share count. Negative means buybacks shrank it.
F-score: Nine pass/fail tests of profitability, funding and efficiency. 8–9 is strong, 0–2 weak.
Industry: The industry the company reports under, from its SEC filing code. Click it to see its peers.
Colours and dashes: Green is up or growing, red is down or shrinking. — means no data, or a P/E that is not meaningful (losses, or above 200).
Units: M = millions, B = billions, T = trillions, in USD. Fundamentals use the latest fiscal year. Use “Edit columns” to show more figures, hide some or change their order.